Trial Profile

Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary)
Indications Dermatomyositis
Focus Registrational; Therapeutic Use
Acronyms ProDERM
Sponsors Octapharma

Most Recent Events

17 Jan 2024 Results examining the safety and tolerability of IVIg, published in the Arthritis Research and Therapy
15 Nov 2023 Results of a post-hoc analysis assessing myositis autoantibodies as predictors of response to IVIG presented at the ACR Convergence 2023
03 Jun 2023 Post -hoc results presented at the 24th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com